trastuzumab
Not Tagged
['herceptin', 'biomarker', 'tnbc', 'immune therap']
 #asco23 biomarkers takeaways: her2+ tils are prognostic but there is no group that does not benefit from herceptin. in tnbc, high proliferation may predict for immune therapy benefit, (but it also predicts for chemo benefit and this is only an exploratory analysis).
Breast med oncology, chief hem/onc @NYPBrooklyn, prof clinical med @WeillCornell, ethics/spirituality in medicine; long time NY #Jets sufferer; tweets my own